This move is archived. Current quotes and coverage live on the stock page.
Follow HLS
HLS Therapeutics Inc faces a notable drop in its stock price, reflecting investor concerns amidst a challenging market environment.
HLS Therapeutics Inc (HLS.TO) experienced a decline of 2.38% in its stock price during the last trading session, closing at CA$4.30. This downward movement raises questions about the company's performance and the broader market sentiment.
Investor takeaway: Investors should monitor HLS Therapeutics closely, especially in light of its recent financial results and the competitive landscape for its cardiovascular products.
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$137.35M
52W high
$5.38
52W low
$3.56
1W change
-6.80%
Beta
0.71
Analyst Price Targets
Based on analyst covering HLS · as of Nov 6, 2026
Wall Street analysts forecast HLS stock price to rise 66.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.40
+66.7% Upside
Previously C$7.35 on Nov 5, 2026
Current Price
C$4.44
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
47.3%
Annualized
90-Day Vol
39.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.71 | C$4.00 – C$5.55 |
| 60 trading days | C$5.00 | C$3.97 – C$6.30 |
| 90 trading days | C$5.31 | C$4.00 – C$7.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc down 2.38% in one trading day
The stock's decline reflects ongoing investor concerns, particularly as the company works to establish its new product in a competitive market.
Bull case
The company recently reported a 2% increase in year-over-year revenue, which suggests there may be growth opportunities ahead, especially with the launch of NILEMDO™ in Canada.
Bear case
Despite the recent revenue growth, HLS Therapeutics is still dealing with a negative profit margin and faces challenges in maintaining investor confidence amid market volatility.
Market Performance Overview
HLS Therapeutics Inc's stock closed down 2.38% at CA$4.30, reflecting a broader trend of investor caution. The decline comes despite a recent report showing a 2% increase in year-over-year revenue, raising questions about the company's ability to maintain momentum.
Recent Developments
The company recently launched NILEMDO™ in Canada, a new treatment aimed at reducing LDL-C levels. However, the market's reaction suggests that investors remain skeptical about the long-term impact of this launch on the company's financial health.
Looking Ahead
As HLS Therapeutics navigates a challenging market landscape, investors should keep an eye on upcoming financial results and product performance. The company's ability to convert recent product launches into sustained revenue growth will be crucial for regaining investor confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
